The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
part 3:
djt genetics programme
the genetics programme has delivered third generation seeds with at least 87.5 per cent. ****geneity. djt has created and documented the proprietary breeding protocols. djt intends to use these in partnership with a university genetics department to obtain access to third party grant funding to progress the programme to the sixth generation. following which, it would commence field trials with the resulting plants. the company will begin applying for government-backed grant funding opportunities as soon as the relevant annual grant calls are published. collectively, the impact of these decisions at djt plants has been a reduction of approximately £60,000 per month of operating expenses for the group.
ananda's ceo, melissa sturgess, commented: "the response to the announcement earlier this month that the endometriosis trial is being funded by nhs scotland has been extraordinarily encouraging. suddenly, we are experiencing awareness that a cannabinoid medicine has the potential to be a mainstream licenced medicine for this condition which affects more than 190 million women globally.
"the decision to pause medical cannabis flower operations at djt plants until there is a clear path to a profitable operation is the right one. it has resulted in the development of an innovative and cost-effective strategy to pursue the breeding programme with grant funding, which reduces group costs significantly and gives us the agility and flexibility required to properly pursue the clinical trials with the aim of nhs acceptance."
to stay abreast of the latest developments at ananda, we encourage you to follow our social media channels which are:
• instagram: htps://instagram.com/anandadevelopments?igshid=ymmymta2m2y=
• linkedin: htps://www.linkedin.com/company/anadevelopments/
• twitter: htps://twiter.com/anandaplc?s=21&t=9yeic_xycfzgdn7j26sfua
-ends-
the directors of the company accept responsibility for the contents of this announcement.
Part 2:
The endometriosis trial will assess the efficacy of MRX1 in the management of pain in 100 patients with endometriosis.
The CIPN (Chemotherapy Induced Peripheral Neuropathy) trial will assess the properties of MRX1 in affecting pain and mood in 100 patients who have CIPN.
The Company has commenced discussions with key clinical investigators for further RCT's using MRX1 for the treatment of other chronic inflammatory pain conditions, including a possible trial for fibromyalgia. NICE (The National Institute for Clinical Excellence) has made the clinical and cost effectiveness of cannabidiol for fibromyalgia a key recommendation for research. MRX1 and MRX2 cannabidiol medicines were launched in the UK as unlicenced medicinal products or specials at the end of July. Currently the oils are on the list of prescribable medicines of three private pain and medical cannabis clinics in the UK.
Ananda's objective is to obtain MHRA (Medicine and Healthcare products Regulatory Agency) licences for the medicines so that they can be prescribed in the NHS for the specific conditions which would likely result in wider use of the Company's cannabidiol medicines.
DJT medical cannabis ower, cultivation, and processing
DJT's 2023 medical cannabis cultivation trials are now complete. The trials have proven that the low capital, low operating cost cultivation model delivers premium quality medical cannabis flower. A large database of detailed standard operating procedures and protocols has now been developed. The next step towards producing medical cannabis flower for sale in the UK is to construct a GMP manufacturing facility. Ananda does not currently see sufficient demand for cannabis flower in the UK to justify the required capital expenditure so headcount at the Lincolnshire facility has been reduced. Ananda will continue to monitor market demand for cannabis flower before, subject to funding, progressing construction and licencing of a GMP facility. Ananda sees potential for the DJT facility to be used to supply cannabinoid APIs for its own MRX medicines.
Part 1:
Today 07:00
RNS Number : 8736K
Ananda Developments PLC
31 August 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Shareholder Update
Ananda Developments plc (AQSE:ANA), a company developing cannabinoid medicines for the treatment of chronic inflammatory pain conditions, provides the following corporate update.
Highlights
• The Chief Scientist Office, responsible for funding research in NHS Scotland, has been confirmed as the funder of the endometriosis randomised controlled trial ("RCT") using MRX1.
• Ananda is pursuing additional investigator led RCTs (Randomised Controlled Trials) evaluating MRX products in inflammatory pain conditions.
• Medical cannabis plant cultivation trials complete.
• Medical cannabis genetic breeding programme reached third generation of plants. Breeding protocol fully established.
• MRX1 and MRX2 cannabidiol medicines available for sale via UK based specials pharmacies.
MRX: cannabinoid unlicensed medicines
MRX1 has been selected to be used in two Phase 2 RCTs being conducted by leading clinicians from The University of Edinburgh. Drug supply agreements are being finalised and the MRX1 formulation is undergoing stability trials ahead of patient recruitment. Stability trials are being undertaken to align with the test method, outlined in the EU Pharmacopoeia, that will come into force in the EU in July 2024. Ananda expects these methods to apply in the UK at that time. The MRX medicines are being manufactured for the RCTs by a contract manufacturing organisation (CMO), using externally sourced GMP (Good Manufacturing Practice) grade active pharmaceutical ingredients (APIs).
Referring to a fund raise as ‘coming round with the begging bowl’ is a strange way to refer to a company in development that will inevitably need to raise funds to grow and expand.
I don’t think anyone particularly enjoys the dilution that comes with small company development but how else do they grow? What alternative method of funding do you propose?
If you are so against fund raises then why not ditch your shares snd invest in a company that is already established and can self fund growth from any retained profits.
Btw, not saying you -personally- have a perennial downer on this, just the general 'you' as in why would anyone in general continue to hold something with serious funding doubts? This makes no sense to me, if in doubt, get out is my motto.
I have a small, comfortable amount in this so am prepared to let it ride and just watch the progress. It won't be overnight, it'll take time and results-based effort.
If you have 'big negatives' why continue to invest in something you have a perennial downer on?
In any case, ANA has the rare distinction of a small company that is not endlessly and recklessly tapping up shareholders for funds, unlike others. They've managed to get themselves to serious clinical medical trials in Scotland with an eye on the NHS and without bothering shareholders much at all.
Yes, there are a lot of shares, yes, many are in sticky hands (there are pros and cons to that) and yes it's an incredibly boring and frustrating plod, yes it's annoying that we seem stuck on 0.0050p after years of progress . But the stickies are there because they've invested in the end goal. Is it worth a punt? You decide. Nobody has to sink much money in here, it's dirt cheap and not requiring of anyone putting a pound of flesh on the table. It's a company that you'd buy a few within your comfort zone, put away for a year at least and reassess. That's not to say things won't happen in the meantime. Good, sp driving things. And yes they may fundraise but again, it's not like, oh sheet, they're coming round with the begging bowl AGAIN. I used to invest in AIM miners and we were tapped up for brass nearly every 6 months, it was horrendous. It's a breeze here thus far in comparison .
I’d prefer the Options and Warrants to be converted by the holders. There would be more than enough to expand and fund operational costs if they were all converted. Better that than an open market placing, for the same reasons given earlier re sticky hands. All amounts to the same thing in terms of dilution but it’s the ongoing impact of sellers from a placing that is the big negative for me.
The shares issued to Charles were in return for the £2.4m loan he provided to the company, which allowed them to build the Research facility, recruit the likes of Nigel Gale and Steve Murray to drive forward their plant development and to fund operations for over 2 years.
The alternative would have been to go to open market to fund raise with the resultant shares likely to be in loose hands who would drop shares for years on end. At least with the Charles loan and share holding they are likely to be held longer term.
If you are so opposed to the Charles loan and share holding, how would you propose the company to fund its development and growth?
I remember the days when an Rns like this would have rocketed the SP back before Charles Morgan came in and had his way with the number of shares in issue.
Today 07:00
RNS Number : 2739J
Ananda Developments PLC
15 August 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
NHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL
Ananda Developments plc (AQSE: ANA), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of chronic, complex inflammatory pain conditions, is pleased to announce that the Chief Scientist Office ("CSO"), which is part of the Scottish Government Health Directorate and is responsible for funding research in NHS Scotland (NHS) is providing the non-dilutive funding for the previously announced endometriosis randomised controlled trial ("RCT") using Ananda's MRX1 sublingual cannabidiol oil. The CSO is providing £300,000 to conduct the trial using Ananda's patent pending MRX1 formulation and matching placebo.
The endometriosis RCT will be conducted by Dr Lucy H R Whitaker (BSc (Hons) MB ChB MSc MD MRCOG), NES CSO Clinical lecturer in Obstetrics and Gynaecology at The University of Edinburgh. Dr Whitaker is supported by Professor Andrew W Horne (PhD, FRCOG, FRCP Edin, FRCSEd, FRSE), Professor of Gynaecology and Reproductive Sciences at The University of Edinburgh. Prof Horne is also Co-director of EXPPECT Edinburgh, Specialty Advisor to Scotland's Chief Medical Officer for Obstetrics and Gynaecology, President-elect of the World Endometriosis Society & Co-Editor in chief of Reproduction and Fertility. The 100 endometriosis RCT participants will take Ananda's patent pending MRX1 cannabidiol oil or matching placebo.
Melissa Sturgess, CEO of Ananda, commented "Our objective is to have MRX1 included by the NHS as an efficacious and cost-effective treatment for pain associated with endometriosis. Getting NHS funding for this trial using MRX1 is a clear statement of the importance of endometriosis as a public health issue and we believe clearly demonstrates the interest in the use cannabidiol as a potential treatment for endometriosis and other complex chronic inflammatory pain conditions by the UK's public health bodies. The chronic, complex inflammatory pain market was recently estimated (https://www.england.nhs.uk/blog/anthony-woolf/) to be worth at least £5 billion per annum in the UK alone."
For further information about the use of MRX1 in clinical trials please contact nick.clarkson@mrxmedical.com and for all other MRX enquiries, including for MRX1 to be prescribed by specialists, please contact Jack@anandadevelopments.com
Further information on the trial:
TCS/22/28 - ENDOCAN-1: A Pilot Randomised Controlled Trial Of The Efficacy Of A Cannabinoid Oral Tincture In The Management Of Endometriosis-Associated Pain.
--------------------------------------------
More at RNS tab above...
Today 17:44
RNS Number : 8031H
Ananda Developments PLC
31 July 2023
31 July 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Completion of Audit, Publication of Annual Report and Accounts and Notice of Annual General Meeting
Further to the announcement of its 2022/23 unaudited preliminary results on 13 July 2023, Ananda announces that the audit for the year ended 31 January 2023 has now been completed. Adjustments have been made to the previously notified Consolidated Statement of Cashflows and Balance Sheet, which are reflective of adjustments made a part of a review of the acquisition of DJT Group Limited, revised tables are set out below.
The Company's Annual Report and Accounts for the year ended 31 January 2023, together with a Notice of Annual General Meeting, has been published on the Company's website. The notice of Annual General Meeting have also today been posted to, or emailed to, shareholders as appropriate in accordance with the provision in the Company's articles of association on electronic communications.
The Annual General Meeting is due to be held at the offices of Shakespeare Martineau Llp, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR at 2.00pm on 24th August 2023.
Statement of Financial Position...
(Rest see under RNS tab above).
friendly telegram group here for anyone new to investing in ananda developments, or just wants to know more: *************anandadevelopmentsinvestorgroup
Great write up here for Amanda on MRX.
https://www.linkedin.com/posts/melissa-sturgess_ananda-developments-launches-mrx1-and-mrx2-activity-7091763171715108864-l3ks?utm_source=share&utm_medium=member_ios
Well when you've put down the salt that you're aiming at me for some odd reason, I'm sure you're capable of dropping them a line. It's an Ananda company so you can obviously contact HQ and there are numerous ways of contacting MRX, which is basically Ananda, on that page.
Usually people find out what's what for themselves, not sit back, throw shade and then wait for others to ask the questions they themselves are chasing.
Sorry, dunno why the word 'pack' went into caps lock territory, my phone sometimes does this. Nothing intentional meant with that.
Are you a registered medical professional, Gaz? Because that's the only way, by law, you're going to get further info from them about their products via MRX.
If you are, you can apply online at MRX and they'll send you a PACK. The website is not intended to be for the general public and I was aware of that on visiting. It's clearly for industry professionals only.
Great news coming together very nicely
First Cannabinoid Medicines Launched
Today 07:00
RNS Number : 3310H
Ananda Developments PLC
27 July 2023
27 July 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
First cannabinoid medicines launched
Ananda's ambition is to be a leading provider of high-quality cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
Highlights
• Ananda's wholly owned subsidiary MRX Medical Limited (MRX) has today launched its first two cannabinoid medicines MRX1 and MRX2 on to the unlicenced medicinal products (specials) market
• The oils will be listed on the formularies (list of prescribable medicines) of three private pain and medical cannabis prescribing clinics in the UK
• MRX1 has been selected to be used in the two Phase II, double blind, RCTs (Randomised Control Trials) run by researchers at the university of Edinburgh.
Ananda's CEO, Melissa Sturgess, commented: "We are determined to win NHS support for our cannabinoid medicines with our rigorous approach to formulation development, clinical trials and traditional pharmaceutical data collection. We believe that MRX is in the strongest position to do exactly that. With NHS endorsement we can bring these medicines to the millions of people who need them and deliver revenues to Ananda."
Following the signing of the final manufacturing agreement with MRX's contract manufacturing organisation (CMO) on 26 July 2023 after market close, Ananda is pleased to announce that as of today both MRX1 and MRX2 are now available for Specialist doctors to prescribe to their patients.
Both MRX1 and MRX2, as well as a to-be released formulation MRX3 are patent pending. There is a fourth pending patent application which covers MRX's proprietary method for formulating these medicines. MRX1 is also to be used in two Investigative Medicinal Products (IMPs), which will be used in two Phase II RCTs. The RCTs are investigating the efficacy of cannabidiol in treating chemotherapy induced peripheral neuropathy (CIPN) and endometriosis. Both trials are being conducted by world leading clinician investigators at the University of Edinburgh and collectively have received commitments for £1.55m of non-dilutive grant funding.
For all prescriber and clinic enquiries related to MRX medicines please contact Jack Morgan at jack.morgan@anandadevelopments.com. Please also visit the MRX website, www.mrxmedical.com.
-Ends-
Thanks to LSE for arranging this and thanks to everyone who lobbied for it.
See RNS tab above.
This part should be of particular interest anyone wanting to know about commercial sign off:
'On 10th July 2023, Home Office representatives visited DJT Plants' facility. This visit was a compliance visit as per the terms of the DJT licence and standard Home Office practice. Two seasons of cultivation trials have now been undertaken and the genetic stabilisation programme is at the third generation of seeds. As a result, this phase of research is now complete and DJT's costs will reduce whilst the Company continues to plan for commercial cultivation and manufacturing.'
Goofy not goody. Sorry, this ain't a good start for me. :D
Sigh goofy not d
Sorry about the goody formatting. It was copied directly from an RNS and looked fine when I posted it here.
There are just a few links at the end to add:
To stay abreast of the latest developments at Ananda, we encourage you to follow our
social media channels which are:
• Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
• LinkedIn: https://www.linkedin.com/company/anadevelopments/
• Twitter: https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA
-Ends-
The Directors of the Company accept responsibility for the contents of this
announcement.
ANANDA DEVELOPMENTS PLC
The team has also been managing the vegetative and flowering stages of cultivation in
order that harvesting work can be staggered efficiently over time. This minimises
operating costs and increases quality as the team can work steadily and consistently
rather than be rushed if a number of cultivars have to be harvested at the same time. This
is a key KPI for future commercial cultivation. The improvements in plant yield and health
are visibly noticeable when comparing 2022 trial plants with the current trial crops.
Research
RCTs (Randomised Controlled Trials) Using MRX1 Cannabidiol Based Medicaloil
The Company's patent pending MRX1 cannabidiol based medical oil formulation goes onto stability testing on 3 July, 2023, in preparation for being used in the CIPN (Chemotherapy Induced Peripheral Neuropathy) and endometriosis RCTs to be conducted by the University of Edinburgh. Stability testing is required to confirm the medicine's storage requirements and shelf life.
DJT Genetic Stabilisation
The genetics programme is part way through its second cycle with third generation seeds
being produced by some 57 plants. The total number of seed lines in the genetic stabilisation programme is 127 providing DJT with opportunities to develop specialist
genetics in the future. Since commencing the genetic breeding programme in February
2022:
1. The time from germination to seed production has decreased from an average of 95
days to an average of 35 days.
2. The number of seeds produced per plant has increased from 1-10 to approx. 300 seeds per plant. The highest yield to date is more than 1,000 seeds from one plant.
Exercise Of Options
Ananda has received gross funds of £18,812.50 from James Kerr for the exercise of 4,180,455 options at 0.45 pence per share (the "Option Shares"). 4,180,455 Ordinary Shares have been approved for issue to Mr Kerr.
Application for Admission
Application will be made for the Option Shares to be admitted to trading on the Access segment of the AQSE Growth Market. It is expected that admission will become effective on 30 June 2023.
The Option Shares will, on admission, rank pari passu in all respects with the Ordinary Shares in issue and will rank in full for all dividends and other distributions hereafter declared, paid or made on the ordinary share capital of the Company.
Total Voting Rights
Following the issue of the Option Shares, Ananda has 2,878,027,906 Ordinary Shares in issue, each share carrying the right to one vote.
This figure of 2,878,027,906 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
_____________________
Https://anandadevelopments.com/announcements/
26 June 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Operational Update
Ananda's ambition is to be a leading provider of high-quality cannabinoid-based
medicines for the treatment of complex, chronic inflammatory pain conditions.
Highlights
• MRX1 cannabidiol based medical oil on track for commercial launch in July 2023
• Second season of medical cannabis flower cultivation trials underway and
exceeding expectations
• MRX1 cannabidiol medical oil for sale from July 2023 and MRX website on track
for launch in next four weeks
• Genetic programme to stabilise strains accelerating; generating large seed
numbers
Ananda's CEO, Melissa Sturgess, commented: "The NHS spends £5 billion each year
attempting to treat complex, chronic inflammatory pain conditions. If we can solve even
a small portion of that problem with our patent pending cannabidiol-based medicines, we
will be doing very good work for both patients and our shareholders. I am optimistic on
both fronts."
Commercial
MRX: Cannabidiol Based Medical Cannabis Oils
The commercial launch of MRX1 cannabidiol based medical oil is on track to commence in July 2023
and the product will be available for prescribing by specialists from July. The information packs for
prescribers have recently been approved by external legal counsel. In conjunction with the
commercial launch, the MRX website will go live in the next four weeks.
DJT Medical Cannabis Flower, Cultivation, And Processing
At Ananda's UK-based, Home Office licenced cannabis cultivation facility, the team has
been growing three strains of cannabis that meet the need for balanced and high CBD
cultivars in the UK market. The three strains are being grown in Ananda's natural season
cultivation environment, in order to assess the agronomic traits of these strains and to
perfect the growing methodology and Standard Operating Procedures required for
commercial cultivation.
The three cultivars were chosen after analysis of the 2022 field season crop and include
Sage, Apocalypse and Charlotte's Web. Sage and Apocalypse are both balanced CBD:THC
cultivars and Charlotte's Web is a high CBD cultivar.
Ananda's view is that it will deliver high quality, high demand and efficacious product by
focusing on balanced and high CBD producing strains. Whilst there is a large range of high
THC cultivars currently being imported, there is only a small choice of balanced and high
CBD cultivars. Discussions are progressing with clinics and specials manufacturers for
offtake agreements.